US Patent No: 7,902,213

Number of patents in Portfolio can not be more than 2000

Pharmaceutical cream with reduced imiquimod impurities at four months using refined oleic acid

ALSO PUBLISHED AS: 20100120835

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
MEDICIS PHARMACEUTICAL CORPORATIONSCOTTSDALE, AZ119

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Nelson, Robert J Orlando, FL 131 1780
Statham, Alexis S Woodbury, MN 66 340

Cited Art Landscape

Patent Info (Count) # Cites Year
 
3M INNOVATIVE PROPERTIES COMPANY (25)
6,039,969 Immune response modifier compounds for treatment of TH2 mediated and related diseases 191 1997
6,110,929 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 179 1999
6,245,776 Formulations and methods for treatment of mucosal associated conditions with an immune response modifier 184 2000
6,200,592 Immine response modifier compounds for treatment of TH2 mediated and related diseases 83 2000
6,331,539 Sulfonamide and sulfamide substituted imidazoquinolines 172 2000
6,451,810 Amide substituted imidazoquinolines 148 2000
6,656,938 Urea substituted imidazoquinoline ethers 128 2001
6,660,747 Amido ether substituted imidazoquinolines 123 2001
6,664,260 Heterocyclic ether substituted imidazoquinolines 117 2001
6,664,264 Thioether substituted imidazoquinolines 128 2001
6,670,372 Aryl ether substituted imidazoquinolines 122 2001
6,683,088 Sulfonamido ether substituted imidazoquinolines 122 2001
6,756,382 Amide substituted imidazoquinolines 96 2001
6,525,064 Sulfonamido substituted imidazopyridines 144 2002
6,545,016 Amide substituted imidazopyridines 140 2002
6,545,017 Urea substituted imidazopyridines 140 2002
6,664,265 Amido ether substituted imidazoquinolines 128 2002
6,667,312 Thioether substituted imidazoquinolines 127 2002
2003/0199,538 Pharmaceutical formulation comprising an immune response modifier 97 2002
6,677,349 Sulfonamide and sulfamide substituted imidazoquinolines 124 2003
6,797,718 Ether substituted imidazopyridines 94 2003
2004/0091,491 Immunostimulatory compositions and methods of stimulating an immune response 82 2003
6,818,650 1H-imidazo dimers 93 2003
2004/0132,766 1H-imidazo dimers 52 2003
2004/0147,543 Aryl substituted imidazoquinolines 83 2003
 
COLEY PHARMACEUTICAL GROUP, INC. (10)
5,268,376 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines 225 1991
5,266,575 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines 222 1991
5,352,784 Fused cycloalkylimidazopyridines 215 1993
5,446,153 Intermediates for imidazo[4,5-c]pyridin-4-amines 189 1994
5,482,936 Imidazo[4,5-C]quinoline amines 202 1995
6,376,669 Dye labeled imidazoquinoline compounds 157 2000
6,660,735 Urea substituted imidazoquinoline ethers 127 2002
6,677,347 Sulfonamido ether substituted imidazoquinolines 122 2002
6,677,348 Aryl ether substituted imidazoquinolines 122 2002
2004/0176,367 1-Amino 1H-imidazoquinolines 78 2004
 
MEDICIS PHARMACEUTICAL CORPORATION (7)
5,389,640 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 232 1992
5,736,553 Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo?4,5-C!quinolin-4-amine 55 1995
5,939,090 Gel formulations for topical drug delivery 178 1996
6,541,485 Urea substituted imidazoquinolines 135 2000
6,573,273 Urea substituted imidazoquinolines 130 2001
2004/0192,585 Treatment for basal cell carcinoma 77 2004
2007/0167,479 Immune response modifier formulations and methods 46 2005
 
Riker Laboratories, Inc. (4)
4,751,087 Transdermal nitroglycerin delivery system 85 1985
4,698,348 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents 252 1985
4,929,624 Olefinic 1H-imidazo(4,5-c)quinolin-4-amines 251 1989
5,756,747 1H-imidazo?4,5-c!quinolin-4-amines 188 1995
 
Noven Pharmaceuticals, Inc. (3)
5,300,291 Method and device for the release of drugs to the skin 79 1991
6,562,363 Bioadhesive compositions and methods for topical administration of active agents 125 1998
6,638,528 Compositions and methods to effect the release profile in the transdermal administration of active agents 86 2002
 
ALZA CORPORATION (2)
4,746,515 Skin permeation enhancer compositions using glycerol monolaurate 102 1987
6,210,712 Dosage form having first and second coats 43 1998
 
CORIUM INTERNATIONAL, INC. (2)
6,803,420 Two-phase, water-absorbent bioadhesive composition 68 2002
2003/0170,308 Hydrogel compositions 68 2002
 
GALENIX INNOVATIONS (2)
2003/0096,012 Film-forming powder, compositions containing it, methods for their preparation and their uses 39 2002
2003/0124,191 Use of an immediate-release powder in pharmaceutical and nutraceutical compositions 44 2002
 
GRACEWAY PHARMACEUTICALS, LLC (2)
4,689,338 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use 299 1985
5,238,944 Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine 216 1992
 
Minnesota Mining and Manufacturing Company (2)
4,411,893 Topical medicament preparations 63 1982
5,346,905 1-substituted 1H-imidazo-[4,5-C]quinolin-4-amines 221 1992
 
Westwood Pharmaceuticals, Inc. (2)
4,191,767 Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines 41 1977
4,197,403 4-Aminosubstituted imidazo(1,2-A)quinoxalines 37 1977
 
A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESES, RUSSIAN ACADEMY OF SCIENCES (1)
2004/0242,770 Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith 48 2004
 
ABB TECHNOLOGY AG (1)
2004/0089,855 High oleic acid oil compositions and methods of making and electrical insulation fluids and devices comprising the same 30 2003
 
AGIS INDUSTRIES (1983) LTD. (1)
2006/0034,779 Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same 34 2005
 
ASTRA AKTIEBOLAG (1)
6,103,697 Peptides with immunomodulatory effects 34 1997
 
COGNIS CORPORATION (1)
6,498,261 Process for improving color and color stability of oleic acid 30 1995
 
DERMATRENDS, INC. (1)
2003/0072,814 Topical pharmaceutical composition for the treatment of warts 75 2002
 
FUJIMORI KOGYO CO., LTD. (1)
4,686,125 Film laminate for sterile flexible containers 100 1984
 
HENKEL CORPORATION (1)
2002/0128,345 Hot melt adhesives for dermal application 35 2000
 
Hisamitsu Pharmaceuticals (1)
7,504,114 Preparations for percutaneous absorption 30 2000
 
INTERCONNECTRON GMBH (1)
6,425,776 Circular plug and socket connector for producing electrical line connections 33 2000
 
KYTHERA BIOPHARMACEUTICALS, INC. (1)
2005/0201,959 Methods and compositions for altering skin coloration 31 2004
 
LTS LOHMANN THERAPIE-SYSTEME AG (1)
7,056,528 Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin 32 2000
 
LUITPOLD PHARMACEUTICALS, INC. (1)
5,919,815 Taxane compounds and compositions 107 1996
 
MEPHA AG (1)
2006/0039,931 Stable cream preparations of phenyl-pyridone compounds for topical application 33 2003
 
MITSUI CHEMICALS, INC. (1)
5,532,030 Polyolefin multilayer laminate, vessel and packaging material 67 1995
 
Nippon Oil and Fats Co., Ltd. (1)
4,601,856 Method of purifying oleic acid 35 1985
 
NUVO RESEARCH INC. (1)
2005/0276,842 Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same 51 2005
 
PERICOR SCIENCE, INC. (1)
6,267,957 Attaching agents to tissue with transglutaminase and a transglutaminase substrate 81 1999
 
PERRIGO ISRAEL PHARMACEUTICALS LTD. (1)
2006/0024,243 Foamable compositions containing nitro-imidazoles, processes for preparing same and methods of treatment utilizing same 30 2005
 
PHARMACIA & UPJOHN COMPANY (1)
2003/0211,163 Combination antiviral therapy 31 2003
 
Purcell Jojoba International, LLC (1)
6,559,182 Method for treatment of enveloped viruses using jojoba oil esters 32 2001
 
RANBAXY LABORATORIES LIMITED (1)
2005/0037,030 Stable topical formulation of clarithromycin 30 2004
 
SHISEIDO COMPANY, LTD. (1)
5,472,982 Emulsified external treatment composition containing diclofenac sodium 31 1993
 
SOLVAY PHARMACEUTICALS GMBH (1)
4,722,941 Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof 94 1978
 
TAKEDA CHEMICAL INDUSTRIES, LTD. (1)
4,695,465 Soft patch 113 1985
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (1)
6,194,425 Imidazonaphthyridines 177 1998
 
The Procter & Gamble Company (1)
5,008,110 Storage-stable transdermal patch 94 1988
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
2005/0175,630 Immunogenic compositions and methods of use thereof 41 2004
 
THERATECH, INC. (1)
4,863,970 Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols 165 1988
 
VIRUN, INC. (1)
2005/0281,772 Compositions for mucosal delivery of agents 53 2005
 
Warner-Lambert Company (1)
4,908,389 Penetration enhancement system 50 1986
 
Other [Check patent profile for assignment information] (2)
2003/0026,794 Selective enzyme treatment of skin conditions 38 2001
2003/0059,471 Oral delivery formulation 71 2001

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
3M INNOVATIVE PROPERTIES COMPANY (16)
8,378,102 ] ring compounds and methods 0 2006
8,658,666 Substituted imidazoquinolines and imidazonaphthyridines 0 2006
8,343,993 Hydroxyalkyl substituted imidazonaphthyridines 0 2006
8,178,677 Hydroxyalkyl substituted imidazoquinolines 0 2006
8,158,794 Hydroxyalkyl substituted imidazoquinoline compounds and methods 0 2006
8,476,292 Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods 0 2006
8,188,111 -imidazo[4,5-c]quinolin-1-yl)butyI]methanesulfonamides and methods 0 2006
8,088,790 -imidazoquinolines and methods 2 2006
8,329,721 -imidazonaphthyridines and methods 0 2007
8,178,539 ]phenalenes and methods 0 2007
8,541,438 Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines 0 2010
8,263,594 Aryloxy and arylalkyleneoxy substituted imidazoquinolines 0 2011
8,207,162 ] ring compounds 1 2011
8,350,034 Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds 0 2011
8,377,957 Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods 0 2011
8,546,383 Chiral fused [1,2]imidazo[4,5-c] ring compounds 0 2012
 
MEDICIS PHARMACEUTICAL CORPORATION (2)
8,598,196 Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy 0 2012
8,642,616 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 0 2012

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Sep 8, 2014
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 8, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 8, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00

Full Text

 
loading....